Genentech Resumes Xolair Phase IIIb Trial After Clinical Hold Is Lifted
Executive Summary
Genentech has resumed development of Xolair following the lifting of a clinical hold, VP-Medical Affairs Stephen Dilly, MD, said at the Robertson Stephens Medical Conference in New York Nov. 29. "We addressed the questions that FDA posed...and now the clinical hold has been lifted and we're in a position to implement our Phase IIIb program as planned," he reported.
You may also be interested in...
Genentech/Novartis Xolair Approval Could Be Delayed Until Early 2002
Genentech/Novartis Xolair (omalizumab) approval could be pushed back to early 2002 as the companies prepare to submit additional safety data to FDA.
Genentech/Novartis Xolair Approval Could Be Delayed Until Early 2002
Genentech/Novartis Xolair (omalizumab) approval could be pushed back to early 2002 as the companies prepare to submit additional safety data to FDA.
Genentech Xolair May Get FDA Advisory Committee Review In April
Genentech is planning to submit additional platelet monitoring data from trials of its asthma agent Xolair in time for a potential FDA advisory committee review in late April. FDA has tentatively scheduled a meeting of its Pulmonary-Allergy Drugs Advisory Committee for April 26-27.